The Biotech Bargain

By: Josh Sloat

How Patents Help Turn Risk Into Medicine

Do patents make drugs more expensive? And what role does intellectual property play in getting new medicines from the lab bench to patients?

The questions have never been more timely. Biopharmaceutical innovation sits at the center of some of our biggest public policy debates. Drug pricing, access, generic competition, university research, venture funding, AI-driven discovery, follow-on research, and the future of biotech startups. And in the middle of those debates, patents are often reduced to slogans like patent monopolies and ever-greening and are assigned the political blame for high drug prices and limited patient access to medical breakthroughs. 
​

​​But the real system is much more complicated. Modern drug development is extraordinarily expensive, uncertain, regulated, and risky. A promising discovery may begin in a university lab, move through a startup, require venture financing, depend on partnerships with larger pharmaceutical companies, survive years of clinical testing, and then still face manufacturing approval, reimbursement, safety monitoring, and market adoption hurdles.

Along that path, intellectual property is not just a prize at the end. It can be the asset that allows investment, collaboration, disclosure, licensing, specialization, and commercialization to happen in the first place. At the same time, the public has a legitimate interest in access, affordability, competition, and generic entry. So the policy challenge is understanding how the system works, what incentives are actually doing, and what can go wrong when lawmakers, courts, and pundits oversimplify the trade-offs.

This is a big conversation, but the through line is simple. If we want more medicines, better medicines, and broader access to medicines, we need to understand the innovation system clearly before we start rewriting the rules.
​

Special Guest: Dr. Bo Heiden

To help us truly understand the critical role of patent protections in the biopharmaceutical ecosystem and what prevailing narratives mean for investors, startups, and biotech R&D, we’re sitting down with Dr. Bo Heiden, one of the leading thinkers working at the intersection of intellectual property, innovation strategy, and life sciences policy. Dr. Heiden is the co-director of the Eira Initiative, a project out of the Berkeley Policy Institute, the Executive Director for the Tusher Strategic Initiative for Technology Leadership at Berkeley’s Haas School of Business, the Co-Director of the Center for Intellectual Property (CIP) at University of Gothenburg, and the Co-Chair of the Technology, Innovation, and Intellectual Property program at the Classical Liberal Institute at the NYU School of Law.
​

Episode Overview

In this wide-ranging conversation on all things drug patents, we discuss the following with Bo:

• Drug price and access concerns, as they pertain to patents.
• The economic realities that make drug development a uniquely risky investment problem.
• The CliffsNotes history of why the modern biotech system emerged so strongly in the United States.
• What policymakers often miss in narratives around evergreening and patent monopolies, and how those narratives may now be pushing policy in directions that could undermine the very startup and R&D ecosystem we all depend on for advancements in medicine.
• The Supreme Court’s recent Hikma decision and what it means for skinny labels, induced infringement, and generic competition.
• Practical takeaways on two of the hottest areas in the market: AI-driven drug discovery and the evolving GLP-1 regulatory and generic landscape.

​

How to Listen

Patently Strategic is available on all major podcasting directories, including Apple Podcasts and Spotify. We're also available on 12 other directories including Stitcher, iHeart Radio, and TuneIn, so you should be able to find us wherever you listen to podcasts.
​

Mossoff Minute: The Democratization of Invention

In this month's Mossoff Minute, Professor Adam Mossoff discusses the democratization of invention sparked by American independence. 

Resources.

Related Episodes

• Fortifying Life Science Patents. Practical application tips for addressing eligibility and enablement issues in life science patents.
• SCOTUS in Focus. Amgen v. Sanofi and the future of pharma patents.
• Predictable Results from Unpredictable Arts. Patenting Biological, Chemical, and Emerging Technologies.
• What Investors Want in Patents for key insights from an investor on how angels and VCs think about your patent portfolio.
• Government Grants and Patent Rights for a deep dive into IP ownership implications for grants like SBIR and STTR. 
• Patent Wars. More in-depth discussion around anti-patent narratives. 
• Why Patents Exist. Focuses on the genesis of the U.S. system.

Related Reading

• How to Read Chemical and Drug Patents
• Drug Patents and the FDA: Timelines, Exclusivity, and Extensions

Transcripts​
We're providing computer-generated transcripts for improved accessibility and additional reference opportunities.